Testing the Addition of an Anti-cancer Drug, Hu5F9-G4 (Magrolimab), to the Usual Chemotherapy Treatment (Mogamulizumab) in T-Cell (a Type of Immune Cell) Lymphoma That Has Returned After Treatment or Does Not Respond to Treatment
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Michael S Khodadoust
City of Hope Comprehensive Cancer Center LAO
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
18 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- City of Hope Comprehensive Cancer Center
Duarte, California, United States
- Los Angeles General Medical Center
Los Angeles, California, United States
- Usc / Norris Comprehensive Cancer Center
Los Angeles, California, United States
- Stanford Cancer Institute Palo Alto
Palo Alto, California, United States
- Northwestern University
Chicago, Illinois, United States
- Washington University School of Medicine
St Louis, Missouri, United States
- Memorial Sloan Kettering Basking Ridge
Basking Ridge, New Jersey, United States
- Memorial Sloan Kettering Monmouth
Middletown, New Jersey, United States
- Memorial Sloan Kettering Bergen
Montvale, New Jersey, United States
- Memorial Sloan Kettering Commack
Commack, New York, United States
- Memorial Sloan Kettering Westchester
Harrison, New York, United States
- Laura and Isaac Perlmutter Cancer Center at Nyu Langone
New York, New York, United States
- Memorial Sloan Kettering Cancer Center
New York, New York, United States
- Nyp/weill Cornell Medical Center
New York, New York, United States
- Memorial Sloan Kettering Nassau
Uniondale, New York, United States
- Wake Forest University Health Sciences
Winston-Salem, North Carolina, United States
- University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, United States
- University of Wisconsin Carbone Cancer Center - University Hospital
Madison, Wisconsin, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 6 Apr 2021
- Primary completion
- 24 Oct 2024
- Completion
- 24 Oct 2024
- Last update posted
- 16 Oct 2025
- Registered enrollment
- 8
- Registry id
- NCT04541017
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.